Results 171 to 180 of about 3,635,661 (309)

Plasma extrachromosomal circular DNA as a biomarker in EGFR‐targeted therapy of non‐small cell lung cancer

Molecular Oncology, EarlyView.
Detection of extrachromosomal circular DNA (eccDNA) in plasma samples from EGFR‐mutated non‐small cell lung cancer patients. Plasma was collected before and during treatment with the EGFR‐tyrosine kinase inhibitor osimertinib. Plasma eccDNA was detected in all cancer samples, and the presence of the EGFR gene on eccDNA serves as a potential biomarker ...
Simone Stensgaard, Sarmad Mehmood, Eva Boysen Fynboe Ebert, Peter Meldgaard, Anindya Dutta, Boe S. Sorensen   +5 more
wiley   +1 more source

Decentralized Clinical Trials in Pediatrics: Is Italy Ready? [PDF]

J Clin Med
Paternuosto G, Flamigni A, Zanier M, Bonifacio B, Schillani G, Cirino M, Krcalic S, Tommasi S, Tizi F, Arbo A, Zanon D, Maestro A.   +11 more
europepmc   +1 more source

Screening for lung cancer: A systematic review of overdiagnosis and its implications

Molecular Oncology, EarlyView.
Low‐dose computed tomography (CT) screening for lung cancer may increase overdiagnosis compared to no screening, though the risk is likely low versus chest X‐ray. Our review of 8 trials (84 660 participants) shows added costs. Further research with strict adherence to modern nodule management strategies may help determine the extent to which ...
Fiorella Karina Fernández‐Sáenz, Laura de la Torre‐Perez, David R Baldwin, Carlijn van der Aalst, Mangesh Thorat, David Ritchie, Andre L Carvalho, Carolina Espina, Ivan Solà, Carlos Canelo‐Aybar, Moira Magdalena Pissinis, Pablo Alonso‐Coello, Ana Carolina Pereira Nunes Pinto   +12 more
wiley   +1 more source

Representation of Older Adult Patients in Clinical Trials. [PDF]

Clin Transl Sci
Haertter S, Mallalieu NL, Saleh S, Goldsmith P, Sane R, Cook J.   +5 more
europepmc   +1 more source

Glycosylated LGALS3BP is highly secreted by bladder cancer cells and represents a novel urinary disease biomarker

Molecular Oncology, EarlyView.
Urinary LGALS3BP is elevated in bladder cancer patients compared to healthy controls as detected by the 1959 antibody–based ELISA. The antibody shows enhanced reactivity to the high‐mannose glycosylated variant secreted by cancer cells treated with kifunensine (KIF).
Asia Pece, Giulio Lovato, Ilaria Cela, Arianna Mercatelli, Benedetta Ferro, Jussi Nikkola, Sara Pagotto, Tommaso Grottola, Vincenzo De Laurenzi, Rossella Cicchetti, Antonio Marchetti, Luigi Schips, Rossano Lattanzio, Stefano Iacobelli, Emily Capone, Peter Black, Mads Daugaard, Michele Marchioni, Gianluca Sala   +18 more
wiley   +1 more source

Sharing Data from Cardiovascular Clinical Trials--A Proposal. [PDF]

, 2016
Academic Research Organization Consortium for Continuing Evaluation of Scientific Studies--Cardiovascular (ACCESS CV), Armstrong, PW, Bhatt, DL, Braunwald, E, Camm, AJ, Fox, KA, Gibson, M, Harrington, RA, Hiatt, WR, James, SK, Kirtane, AJ, Leon, MB, Lincoff, AM, Mahaffey, KW, Mauri, L, Mehran, R, Mehta, SR, Montalescot, G, Nicholls, SJ, Patel, MR, Perkovic, V, Peterson, ED, Pocock, SJ, Roe, MT, Sabatine, MS, Sekeres, M, Solomon, SD, Steg, G, Stone, GW, Van de Werf, F, Wallentin, L, White, HD   +31 more
core   +1 more source

Survivin and Aurora Kinase A control cell fate decisions during mitosis

Molecular Oncology, EarlyView.
Aurora A interacts with survivin during mitosis and regulates its centromeric role. Loss of Aurora A activity mislocalises survivin, the CPC and BubR1, leading to disruption of the spindle checkpoint and triggering premature mitotic exit, which we refer to as ‘mitotic slippage’.
Hana Abdelkabir, Shalitha Wickrama Arachchige, Sally P. Wheatley   +2 more
wiley   +1 more source

Are investigator-initiated clinical trials becoming an 'endangered species'? [PDF]

RMD Open
Marzo-Ortega H, De Marco G.
europepmc   +1 more source

O4‐05‐05: Free and Cued Selective Reminding Test as an Inclusion Criterion for Early Alzheimer's Disease Clinical Trial Populations [PDF]

, 2016
Janice Smith, Chris J. Edgar, Robert Lasser, Shuguang Sun, Fabian Model, Thomas Blaettler   +5 more
openalex   +1 more source

CDK11 inhibition induces cytoplasmic p21WAF1 splice variant by p53 stabilisation and SF3B1 inactivation

Molecular Oncology, EarlyView.
CDK11 inhibition stabilises the tumour suppressor p53 and triggers the production of an alternative p21WAF1 splice variant p21L, through the inactivation of the spliceosomal protein SF3B1. Unlike the canonical p21WAF1 protein, p21L is localised in the cytoplasm and has reduced cell cycle‐blocking activity.
Radovan Krejcir, Lukasz Arcimowicz, Lucia Martinkova, Vaclav Hrabal, Filip Zavadil Kokas, Tomas Henek, Martina Kucerikova, Ondrej Bonczek, Pavlina Zatloukalova, Lenka Hernychova, Philip J. Coates, Borivoj Vojtesek, David P. Lane   +12 more
wiley   +1 more source